Genentech Presents Five-Year Data on Susvimo, Highlighting Long-Term Outcomes in Wet AMD

At the 2025 American Society of Retina Specialists (ASRS) annual meeting in Long Beach, CA, Genentech presented new five-year results from its phase 3 Portal study, reaffirming the long-term efficacy, safety, and durability of Susvimo (ranibizumab injection) for treating wet age-related macular degeneration (AMD).

The Portal trial is an extension of the phase 3 Archway study and includes 352 patients previously enrolled in Archway. According to Genentech, approximately 95% of patients treated with Susvimo every six months required no supplemental treatment between refills, reflecting a substantial reduction in treatment burden compared to monthly anti-VEGF intravitreal injections.

“These long-term results reinforce Susvimo’s ability to maintain vision and retinal drying over a long period of time for people with wet AMD, the leading cause of vision loss in people over age 60,” said Levi Garraway, MD, PhD, Chief Medical Officer and Head of Global Product Development at Genentech.

Visual and Anatomical Outcomes at Year 5

The five-year results demonstrated strong and sustained visual and anatomical outcomes in both the original Susvimo cohort and those who transitioned to the treatment. In the Susvimo cohort, the baseline best corrected visual acuity (BCVA) was 74.4 letters, which declined to 67.6 letters at year five, with a central subfield thickness (CST) change of 1.0 µm (95% CI: -13.1, 11.1). In the IVT-Susvimo cohort, baseline BCVA was 76.3 letters, decreasing to 68.6 letters at year five, with a CST change of 10.3 µm (95% CI: -25.7, 5.0).

Importantly, half of all participants maintained 20/40 vision or better at the five-year mark. These findings indicate robust disease control and preservation of visual acuity among patients who initially enrolled with near-peak vision following prior anti-VEGF therapy.

“This study reinforces that continuous drug delivery via Susvimo may lead to more durable outcomes in real-world scenarios than traditional injection regimens,” noted John Kitchens, MD, Retina Associates of Kentucky, during the ASRS presentation.

About Susvimo and the Port Delivery Platform

Susvimo is administered using the Port Delivery Platform, a refillable intraocular implant surgically placed in a one-time outpatient procedure. The device delivers a continuous supply of ranibizumab over six-month intervals, offering a compelling alternative to frequent intravitreal injections for eligible wet AMD patients.

The Archway study (NCT03677934) was a randomized, multicenter, open-label phase 3 trial comparing fixed 6-month Susvimo refills to monthly intravitreal ranibizumab injections in 415 patients. Participants had previously responded to anti-VEGF therapy, receiving an average of five injections before enrollment. The Portal study continues to follow these patients to evaluate long-term safety and efficacy.